Journal of Clinical and Aesthetic Dermatology最新文献_第3页

Don't Let Beauty Blind You: Unveiling Clinical Diagnoses During Cosmetic Dermatology Practice. 不要让美丽蒙蔽你：在美容皮肤科实践中揭示临床诊断。

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

Miguel A Aristizabal, Tara Soto, Leila Tolaymat, Alison J Bruce

引用次数: 0

Young Psoriatic Patients Respond Faster to Dimethyl Fumarate: Age-related Differences in Efficacy and Adverse Events. 年轻银屑病患者对富马酸二甲酯反应更快：疗效和不良事件的年龄相关差异

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

Martina Burlando, Adelaide Algeri, Ilaria Salvi, Emanuele Cozzani, Aurora Parodi

{"title":"Young Psoriatic Patients Respond Faster to Dimethyl Fumarate: Age-related Differences in Efficacy and Adverse Events.","authors":"Martina Burlando, Adelaide Algeri, Ilaria Salvi, Emanuele Cozzani, Aurora Parodi","doi":"","DOIUrl":"","url":null,"abstract":"Background: Dimethyl fumarate (DMF) is an oral treatment approved by the European Medicines Agency (EMA) to treat moderate-to-severe plaque psoriasis among adult patients.Objectives: This study aims to evaluate sociodemographic, anthropometric, and medical characteristics in patients with psoriasis without previous history of traditional systemic therapy and to observe if the efficacy or AEs of dimethyl fumarate correlate to any of the patients' characteristics.Methods: Ninety-two patients with mild-to-moderate psoriasis were enrolled. Each patient was reviewed at 4, 12, 24 and 36 weeks. The PASI score and any clinical side effects or blood count abnormalities were recorded.Results: After 4 weeks, a decrease in the median value of PASI index was already noticeable (p<0.001). After 12 weeks of treatment, 43.9% of patients reached PASI-50, 12.3% PASI-75. The patients achieving PASI-75 after 12 weeks of treatment were significantly younger than those who did not. Age, BMI index, gender and gastroprotection used were not significantly related to the occurrence of side effects.Conclusion: Profiling of patients could be useful in predicting the response to treatment. In our study, younger patients were found to respond better to dimethyl fumarate.","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 11","pages":"45-49"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A 12-week, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of a Nutraceutical Supplement for Mild to Moderate Non-cystic Acne in Young Adults. 一项为期12周、随机、双盲、安慰剂对照的研究：一种营养补充剂治疗年轻人轻度至中度非囊性痤疮的安全性和有效性。

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

Glynis Ablon

{"title":"A 12-week, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of a Nutraceutical Supplement for Mild to Moderate Non-cystic Acne in Young Adults.","authors":"Glynis Ablon","doi":"","DOIUrl":"","url":null,"abstract":"Background: Acne vulgaris is a chronic, inflammatory skin disease of the pilosebaceous unit frequently cited as the most common condition diagnosed and treated by dermatologists. Among the many therapies developed for treating acne, none are effective for all patients and new treatments are always being sought. A commercial nutraceutical formulated with vitamins, minerals and a proprietary blend of botanicals has been used as a safe and effective adjunctive therapy for non-cystic acne (Clear Skin Formula; VitaMedica®).Objective: The objective of this study was to evaluate the safety and efficacy of this nutraceutical for treating non-cystic acne.Methods: Subjects randomly received study product (n=26) or placebo capsules (n=14) which were taken daily for 84 days.Results: Treatment with the nutraceutical supplement decreased mean (SD) inflammatory lesions counts from 21.4 (9.3) to 10.4 (8.1) (p=0.0001), decreased non-inflammatory lesion counts from 35.0 (17.1) to 19.5 (13.2) (p<0.0001) versus nonsignificant changes for placebo-treated subjects. Mean baseline IGA scores improved by nearly 1 grade from 2.3 (0.5) to 1.4 (0.6) after 84 days of treatment (p<0.0001) versus no change for subjects treated with placebo. The clinical improvements corresponded with significant improvements in acne-related quality of life measures. The nutraceutical supplement was well-tolerated.Conclusion: These results demonstrate this nutraceutical to be safe and effective adjunctive therapy for patients with non-cystic acne. ClinicalTrial.gov Identifier NCT05879406.","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 11","pages":"24-30"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Randomized, Placebo-controlled Clinical Study Evaluating a Dietary Supplement for Hair Growth. 一项评估膳食补充剂促进头发生长的随机、安慰剂对照临床研究。

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

Jennifer Martin-Biggers, Maria Elisa Barbosa Bueno de Campos

{"title":"A Randomized, Placebo-controlled Clinical Study Evaluating a Dietary Supplement for Hair Growth.","authors":"Jennifer Martin-Biggers, Maria Elisa Barbosa Bueno de Campos","doi":"","DOIUrl":"","url":null,"abstract":"Objective: The desire for improved hair appearance, hair growth and strength are common drivers of supplementation for women experiencing thinning hair. This study examined the effect and safety of a gummy supplement containing B vitamins, zinc and botanical ingredients to improve hair growth, strength and perceived hair quality outcomes.Methods: Healthy females (n=65) ages 18 to 60 with thinning hair were enrolled. After obtaining consent, subjects were evaluated for hair density and tensile strength, then randomized to either a placebo or test product. The test product consisted of two gummies consumed daily. Subjects returned after six months and were again evaluated using phototrichogram for hair density and tensile strength assessment and completed a Self-Assessment Questionnaire reporting hair quality outcomes.Results: Subjects who consumed the test product showed increased hair density between baseline and 6 months (10.1% increase, p<0.001) as well as compared to placebo (2% decrease) (p<0.001). Hair strength tensile measurements were improved in the test group from baseline (10.2% improvement, p<0.002) compared to placebo (9.3% improvement), yet the difference was not statistically significant between groups. Self-assessed improvements in shedding, strength, breakage and brightness were noted compared to the placebo group (p<0.05). There were no adverse events or reactions.Limitations: This study did not assess hair for longer than a six-month period and utilized subject perception for outcomes that differ from clinical assessments.Conclusion: Daily use of a dietary supplement gummy was associated with significant improvement in hair growth as well as self-assessed improvements in hair strength, shedding, and appearance.","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 11","pages":"34-38"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phenotypic Shift during Treatment of Plaque Psoriasis with Ixekizumab. Ixekizumab治疗斑块型银屑病期间的表型转移。

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

Caroline Sulich-Moore, David Altman

引用次数: 0

Maintenance Acne Treatment with Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports. 口服异维甲酸后局部他沙罗汀维持痤疮治疗：综述和病例报告。

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

Shanna M Miranti

{"title":"Maintenance Acne Treatment with Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports.","authors":"Shanna M Miranti","doi":"","DOIUrl":"","url":null,"abstract":"Acne is a chronic dermatologic disorder that can require long-term treatment. To prevent recurrence after oral treatment for severe acne, topical maintenance treatment is recommended; however, there is little guidance or research on maintenance regimens. This article briefly summarizes literature on oral isotretinoin and topical retinoids and presents a case series of patients who received tazarotene 0.045% lotion as maintenance following oral isotretinoin. While oral isotretinoin is efficacious, relapse/remission rates range from 0 to 69 percent depending on the definition of relapse/remission, dose, and duration of treatment/follow-up. In addition, oral isotretinoin is a known teratogen, and long-term use (>2 courses of 15-20 weeks) is not recommended. Topical treatments such as retinoids are recommended for maintenance, and some studies support that adapalene and tazarotene provide a benefit. Tazarotene 0.045% lotion is efficacious and safe, with demonstrated reductions in acne, acne-induced post-inflammatory hyperpigmentation, and melasma. In my clinic, patients with severe recalcitrant acne received once-daily oral isotretinoin for at least 20 weeks until clinically clear. On the day of last isotretinoin dose, once-daily topical tazarotene 0.045% lotion was initiated for 6 to 12 months. A total of 12 patients completed 24.3 (6.7) weeks (mean [standard deviation]) of isotretinoin (cumulative dose: 184.6 [75.1] mg/kg) and 13.0 (6.7) months of post-isotretinoin tazarotene 0.045%. No patients relapsed and all showed subjective visual improvements in acne-related scarring with topical tazarotene. None discontinued tazarotene due to adverse events. These case reports show that tazarotene 0.045% lotion may be an effective and safe treatment to prevent relapse after initial oral isotretinoin treatment.","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 11-12 Suppl 1","pages":"S14-S17"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11698500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of ChatGPT's Responses to Patient Questions on Hidradenitis Suppurativa. ChatGPT对化脓性汗腺炎患者问题的回答分析。

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

Kripa Ahuja, Peter Lio

引用次数: 0

Selected Poster Abstracts from 16^th Annual Dermatology Pearls Conference. 第16届年度皮肤科珍珠会议精选海报摘要。

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

引用次数: 0

Efficacy of Fractional 2940-nm Erbium:YAG Laser Combined with Platelet-Rich Plasma Versus its Combination with Low-Level Laser Therapy for Scar Revision. 分数阶2940 nm铒镱激光联合富血小板等离子体治疗与低水平激光联合治疗疤痕修复的疗效。

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

Mai Abdelraouf Osman, Nevien Ahmed Samy, Ahmed Shami Jasim

{"title":"Efficacy of Fractional 2940-nm Erbium:YAG Laser Combined with Platelet-Rich Plasma Versus its Combination with Low-Level Laser Therapy for Scar Revision.","authors":"Mai Abdelraouf Osman, Nevien Ahmed Samy, Ahmed Shami Jasim","doi":"","DOIUrl":"","url":null,"abstract":"Objective: We sought to compare the safety and efficacy of combining fractional 2940-nm Erbium:YAG (Er:YAG) laser with autologous platelet-rich plasma (PRP) versus its combination with low-level laser therapy (LLLT) for enhancing the outcome of postsurgical and post-traumatic scars.Methods: Fourty-five individuals with post-surgical or post-traumatic scars were randomly divided into three groups: Group A received four fractional Er:YAG laser sessions spaced four weeks apart along with eight sessions of intradermal PRP injections spaced two weeks apart; Group B received four fractional Er:YAG laser sessions spaced four weeks apart along with two sessions of light emitting diode (LED) weekly; and Group C received four fractional Er:YAG laser sessions spaced four weeks apart. Treatment efficacy was evaluated using clinical photographs, Vancouver Scar Scale (VSS), patient satisfaction and histopathology.Results: Regarding vascularity following treatment and the total VSS score, there were significant differences between the studied groups, with scoring was the lowest in Group A compared to Group B and C. Patient satisfaction was the highest in Group A compared to Group B and C.Limitations: A limitation of the current study is the short follow-up period.Conclusion: Scar revision therapy using combined fractional Er:YAG laser with either PRP or LLLT were found to be more efficient and superior to fractional Er:YAG laser alone.","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 11","pages":"39-44"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Xanthelasma Palpebrarum Using Trichloroacetic Acid 80. 三氯乙酸80治疗棕黄斑病。

Journal of Clinical and Aesthetic Dermatology Pub Date : 2024-11-01

Sheetal Sapra, Jennifer Vh Tran, Harmeet Gurm, Mackenzie Eleuterio

{"title":"Treatment of Xanthelasma Palpebrarum Using Trichloroacetic Acid 80.","authors":"Sheetal Sapra, Jennifer Vh Tran, Harmeet Gurm, Mackenzie Eleuterio","doi":"","DOIUrl":"","url":null,"abstract":"Objective: We sought to analyze the effectiveness, recurrence, safety, and patient satisfaction rates following xanthelasma palpebrarum (XP) treatment with trichloroacetic acid (TCA) 80%.Methods: This was a retrospective review of patients treated with TCA 80% for XP between January 2012 and August 2022. A prospective telephone questionnaire was administered to the same patient population to evaluate recurrence, patient satisfaction, and side effects.Results: In total, 77 patients were included in this retrospective review. Most patients received one treatment (n=38; 49.4%) and had XP located bilaterally (n=59; 76.6%) on either the lower eyelids only (n=18; 23.4%) or both the upper and lower eyelids (n=18; 23.4%). Following treatment, 94.2 percent (n=49) of patients expressed satisfaction and 97.2 percent (n=70) displayed a clinician-reported improvement in XP. In the prospective patient questionnaire, the reoccurrence of XP was self-reported in 24.7 percent (n=19) of all patients. The adverse events, reported by the clinician during the retrospective review and the patient during the prospective questionnaire, included erythema (n=2; 2.6%), hyperpigmentation (n=4; 5.2%), hypopigmentation (n=3; 3.9%), and scarring (n=2; 2.6%).Limitations: Limitations may exist due to the retrospective nature of the chart review, missing data, and lack of a comparator cohort. Thus, further studies are required to validate this study's preliminary results.Conclusion: XP has a strong likelihood of recurrence. However, TCA 80% for XP management should be considered as a treatment option due to high patient satisfaction, mild side effects, low cost, and long-term cosmetic results.","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 11","pages":"17-22"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0